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ABSTRACT
Breast cancer is the leading newly diagnosed cancer among women in the United 
States and the second leading cause of cancer deaths.  This makes accurate and early 
diagnosis a priority.  However there is controversy and problems with current diagnostic 
techniques such as a lack of functional measurements from Mammograms and MRI’s. 
Due to these limitations new techniques that overcome these problems such as combined 
Near Infra-red Ultrasound systems are desired.  In this research an integrated dynamic 
Near Infra-red Ultrasound probe was developed to validate the ability of the system to 
produce accurate co-registered results.  A second generation device was developed to use 
in a clinical  trial  that  overcame the limitations of the benchtop probe.  The benchtop 
probe  produced  accurate  absorption  properties  of  an  embedded  tissue  simulating 
phantom.  It was also proved that a user could be trained to follow within an accuracy of 
plus or minus 5% a computer generated pressure profile.  These validation tests allowed 
for the system properties to be optimized prior to the current clinical trial.  Future work 
will include implementing a contrast agent that is sensitive to both Near-Infra red and 
Ultrasound for better functional and structural measurements.  The system could also be 
integrated with current cancer technology such as RF ablation to measure margins pre-
operatively, intra-operatively, and post-operatively.
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1. 0) Motivation and Background
1.1) Motivation
Among women in the United States, breast cancer remains the leading cause of 
newly diagnosed cases  of  cancer  and the  second leading  cause of  cancer  deaths  [1]. 
Detecting breast cancer at an early stage is associated with improved survival. However, 
there is controversy and debate regarding the effectiveness of the existing methods for 
breast cancer screening and early detection. First, statistics show that only about 20% of 
suspicious  mammogram  lesions  in  Breast  Imaging  Reporting  and  Data  System 
(BIRADS) scale 3 to 5 are proven to be malignant on breast biopsy [2]. Second, little is 
known about the effectiveness of the clinical breast examination (CBE) due to the lack of 
performance consistency and standardization [3]. Third, breast self-examination (BSE) 
has not been shown to reduce breast cancer mortality [4]. In light of these limitations, the 
development and refinement of more innovative tools for analyzing the structural  and 
physiologic  characteristic  of  breast  tissue  for  more  precisely  characterizing  and 
differentiating  malignant  tumors,  benign  tumors,  and  normal  breast  tissue  becomes 
increasingly important.  
1.2) Background
The  mostly  commonly  used  modalities  for  breast  imaging  are  mammogram, 
ultrasound (US), and magnetic resonance imaging (MRI) [3]. These modalities primarily 
delineate  the  morphologic  and  structural  characteristics  of  breast  tissue.  However, 
functional and physiologic properties of the breast can be characterized by such tools as 
positron emission tomography (PET) [6]  and dynamic  contrast-enhanced MRI (DCE-
MRI) [7].   But  the  use  of  these methodologies  for  the breast  are  not  yet  considered 
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practical since they are viewed as experimental and are highly cost prohibitive.  This is 
primarily due to the radioactive properties of PET and the high expense of a DCE-MRI 
exam as well as the fact that neither method is universally available. In this regard, it 
remains a priority to develop low cost, portable, noninvasive innovative imaging tools for 
better functional and structural characterization of the breast.
Near  infrared  (NIR)  diffuse  optical  imaging  and  spectroscopy  is  capable  of 
measuring multiple physiologic parameters of biological tissue systems and may have 
clinical  applications  for  assessing  the  development  and  progression  of  neoplastic 
processes, including breast cancer and thus is an emerging modality for breast cancer 
detection in its early stages [5, 6].  NIR light in the range of 700nM-900nM can penetrate 
up to several centimeters into the tissue allowing for imaging of deeper tissue. However, 
the currently available application of near infrared imaging technology for the breast is 
compromised  by low spatial  resolution  due to  the exponential  attenuation  of  light  in 
biological tissue as well as multiple scattering properties. Also, tissue surface condition 
and  the  presence  of  measurement  artifacts  also  make  measurement  accuracy  and 
reproducibility questionable.  In addition, tissue heterogeneities, inter-patient variations 
and cyclic hormone changes all contribute to a lack of universal diagnostic standards.   In 
this regard, tumor geometric features obtained by other imaging modalities such as US 
can be used to guide the NIR image reconstruction [7, 8].  To overcome these limitations 
several  techniques  are  being  developed  such  as  dynamic  NIR  imaging  as  well  as 
combining NIR imaging with another modality such as US, MRI or mammograms to 
create a hybrid imaging system.  Dynamic NIR imaging measures relative changes in 
tissue  properties  such  as  vasculature  and  hypoxia  changes  which  leads  to  a  relative 
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measurement of oxygen and hemoglobin.  With these relative measurements, inter/intra 
patient variation error is minimized and a generalized diagnostic standard can be created. 
[12,13]  Previous research has shown a correlation between high hemoglobin levels and 
low oxygen levels with a tissue lesion being malignant [9].    There are also changes that 
occur  in  tissue  when  a  compressive  force  is  applied,  changing  the  oxygen  and 
hemoglobin levels by as much as 12% [10].  
1.3) Previous Work
Previous work included the construction of a NIR imager for non invasive,  in-
vivo, dynamic detection of biological tissue anomalies [11].  This device was validated in 
a  50  patient  clinical  trial  that  included  applied  compressive  forces  and  continuous 
measurements  of  hemodynamic  responses.   This  trial  indicated  that  suspicious  breast 
lesions have lower [StO2] and higher [HbT] than the surrounding normal breast tissue 
[11,14-17]. The results of this trial  indicate that  pressure-induced [HbT] changes may 
have a correlation with malignant tumor characteristics [11].  The hypothesis that was 
developed as a result of this trial was that changes in the neovasculure process within 
tissue  bearing  cancer  may  cause  an  increase  in  vasculure  resistance  which  causes  a 
slower [Hbt] response than normal healthy tissue.  This hypothesis was also verified with 
animal testing [11].  This clinical trial also resulted in a malignancy index being defined 
in an attempt to create a quantitative value from which patients  can be diagnosed for 
malignancy conditions.
Limitations  and  complications  within  this  system  provide  a  need  for  the 
development of the Dynamic Near-Infrared Ultrasound (DNIRUS) probe.  These include 
the fact the system used in this clinical trial had a relatively slow sampling rate which 
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was prohibitive for real time measurements.  Also, the NIR device utilized a continuous 
wave  function  which  means  that  tissue  scattering  properties  were  not  able  to  be 
measured.   In addition,  the Ultrasound and NIR measurements  were taken separately 
under different loading conditions and thus were not co-registered.  The new DNIRUS 
probe will overcome these limitations. 
 2.0) Theory
The general theory behind the DNIRUS probe is to combine multiple imaging 
modalities to utilize the positive aspects of each system and minimize the inconsistencies 
and problems with each system.  This means obtaining physiologic tissue properties from 
deep tissue penetration from the NIR combined with the structural capabilities of US to 
perform image reconstruction.   Dynamic pressure stimuli  will  also be induced on the 
breast  tissue in order to minimize the variations between patients  and within a single 
patient by measuring relative changes in tissue properties.  
3.0) Materials and Apparatus
3.1) First Design Iteration
The first design iteration of the DNIRUS probe was constructed to validate the ideas 
behind the probe through benchtop testing.  An isometric view of the first generation 
probe can be seen in figure 1.
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Figure 22 Isometric view of DNIRUS probe
The probe consists of a clinical ultrasound that snaps into the white delrin base with a 
custom made snap-in mechanism.  There are two Force Sensing Resistors (FSR) from 
Tekscan Inc. that are attached to the bottom of the probe to measure the pressure changes 
induced during testing.  An optical scanning mechanism is attached to the side of the 
probe that provides a method for manual movement of the NIR sources and detectors as 
well as a measurement knob.  A detailed view of the optical scanning method is seen in 
Figure 2.
Figure 23 Detailed view of Optical Scanning mechanism.
x
The measurement knob with marks for length can be seen in Figure 2.  The knob at the 
end of the device allows for manual movement.  There is a timing belt that attaches the 
motion knob with the lead screws on the bottom of the probe that provide movement to 
the NIR sources and detectors.  In figure three a bottom view of the probe can be seen.   
Figure 24 Bottom view of first design iteration
The timing belt attaches to lead screws on the bottom of the probe and provides opposite 
direction motion through one left handed lead screw and one right handed lead screw. 
The custom made fiber block holders can also be seen in Figure 3 attached to each of the 
lead screws.  The NIR sources are mounted on one of the fiber blocks and the detectors 
are mounted on the other block.  This design was used successfully to obtain verification 
data  that  the device had the potential  to  work as designed.   However,  due to certain 
limitations  of the design,  primarily that  it  was too bulky and complicated to be fully 
utilized in a clinical setting, a second design iteration was necessary.
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3.2) Second Design Iteration
Materials List:
Ultrasound Probe…………………………………Terason model 128-10L5
FSR Sensors………………………………………Tekscan Inc. Model A-201
ISS Tissue Oximeter with auxiliary module...……OxiplexTSTM
Coupled Fiber Optic Cable (.5mm diameter)..….. Industrial Fiber Optics
Fiber Optic Cable…………………………………2mm Industrial Fiber Optics
Custom Machined Parts
 (OSU Chemistry Machine Shop): 
Prisms
Prism Holder
Base Block.
Pressure Cylinder
Handle
Cover 
Machine Screws and Bolts (Various Sizes)…….. McMaster Carr
6v 300mA Power Supply…………………..…… Radioshack
Capacitors…………………………………..…... Radioshack
Resistors……………………………………...…. Radioshack
Electrical Wire…………………………………... McMaster Carr
Electrical Box…………………………………… McMaster Carr
Belleville Washers………………………………. McMaster Carr
Index Matching Gel…………………………….. Industrial Fiber Optics
Optical Epoxy…………………………………... Industrial Fiber Optics
Polishing papers, varying grits…………………. Industrial Fiber Optics
Solid Ultrasound Gel…………………………… Fisher Labs
Liquid Ultrasound Gel…………………………. Fisher Labs
The DNIRUS probe has been designed and constructed to meet certain criteria; 
principally that it is low cost, portable, and non-invasive.  Other desirable characteristics 
that  are  lacking  in  current  breast  cancer  detection  methods  that  are  desired  for  this 
DNIRUS  system  include  improved  reliability  and  combination  of  structural  and 
physiologic modalities.  The objective of the design was to successfully integrate into one 
functional  unit  NIR  and  US  technology  to  measure  tissue  properties  in  response  to 
dynamic  stimuli.   Other  design  requirements  include  being  able  to  change  the  NIR 
source-detector  separation,  which  was  required  to  be  able  to  take  measurements  at 
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varying tissue depths, the ability to accurately reproduce a computer generated pressure 
profile,  clear  high  resolution  US images,  and  high  signal  strength  NIR readings.   In 
addition, the DNIRUS probe will be used for clinical testing, and must be robust enough 
to withstand multiple tests and users.
Figure 25 Isometric View of Second Generation DNIRUS Probe
A  DNIRUS  prototype  includes  adjustable  blocks  for  NIR  source-detector 
separation changes, pressure control (FlexiForce FSR sensors), near infrared sensor heads 
(connected  to  an  OxiplexTS  tissue  oximeter),  and  a  clinical  ultrasound  probe.  The 
prototype  is  primarily  operated  in  compression  mode,  where  NIR diffuse  reflectance 
measurements are collected at different angles around the suspicious lesion for baseline 
data and image reconstruction. Optical and physiologic properties of the breast lesion can 
be reconstructed with the spatial guidance provided by the ultrasound probe. During use, 
NIR  diffuse  reflectance  and  tumor  deformation  are  continuously  monitored  as  the 
DNIRUS probe is compressed against the suspicious breast tissue following a specific 
computer  generated  compression  profile.  Tissue  optical  and  structural  dynamics  are 
calculated based on NIR and ultrasound measurements.
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3.2 a) NIR Function
The NIR function begins at the OxiplexTS tissue oximeter, which provides the 
NIR source at both 690 nm and 830 nm wavelengths.  The NIR is transmitted with a 
coupled  .5mm fiber optic cable from the oximeter to the DNIRUS probe.  This allows 
both wavelengths of light to be transmitted simultaneously along essentially the same 
fiber optic cable.  Once the light is at the sensor head, it must accomplish a 90 degree 
bend.  This manipulation is necessary to maneuver around the ultrasound sensor head, 
keeping the source-detector separation as close as possible, and make the NIR transmit 
from the bottom of the sensor head.    This manipulation is  accomplished by using a 
prism.  This is represented by the dark brown shape in figure 5.
Figure 26 NIR Transmission Evolution
The evolution of the NIR transmission can be found in figure 5.  The original design 
implemented  a  90 degree  bend directly  into  the fiber.  This  caused fiber  damage and 
resulted in a light transmission of about 70% when compared to a straight fiber.  This was 
recognized  as  a  serious  design  flaw  and  the  solution  in  the  center  of  figure  5  was 
implemented.   This  utilized  a  bend  radius  to  transmit  the  light.   This  increased  the 
transmission  to  about  90% versus  a  straight  fiber.   Finally  in  the  second generation 
design, a prism was utilized from which an efficiency of about 97% was realized.
xiv
  The NIR is transmitted through the fiber optics to the top of the prism, and then 
reflects through the prism to exit out the bottom of the probe as shown in Figure 5 by the 
red arrows.  The location of these blocks can be seen in figure 6 represented by the green 
block shapes.  Index matching gel is applied at the contact areas between the prism and 
the fiber optic cable, as well as where the prism contacts the reflective material on the 
side of the block.  This creates a more uniform contact surface and more efficient and 
predictable transmission pattern of light.  
          Figure 27 Fiber Block Positioning
The probe is designed to be able to use 8 sources as shown in figure 7, or one of 
the blocks can be removed to use only 4 sources.  The eight sources are located on the 
right side of the block in figure 7 and the detectors are on the left.
            Figure 28 Source and detector location
xv
For the clinical trial in the summer of 2008, 4 sources were used.  The detector 
fibers used were single 2mm bare fibers.  Because they were bare, a covering was applied 
after installation into the DNIRUS sensor head.  This ensured that no ambient light was 
being picked up by the detector fibers, which minimized the error due to ambient light. 
The detectors also used the same 90 degree mechanism and holding block as the source 
fibers.  Both fiber types were locked into place using a set screw as shown in figure 8. 
The  holding blocks  themselves  are  also  able  to  be locked into place  after  they have 
manually been placed in the appropriate position by using set screws as shown in figure 
8.   
                      
Figure 29 Set Screw locations for Fiber Optics and Block Placement
This allows for the fibers to be removed for maintenance and for the fiber block holders 
to be moved.  This movement creates a change in the source detector  separation and 
changes the depth of the NIR readings.
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3.2 b) Pressure Sensor Function
The  other  main  function  of  the  DNIRUS probe  is  to  monitor  and  record  the 
pressure of the probe against the tissue.  This is accomplished through Force Sensing 
Resistors (FSR) located on the bottom of the probe.  The general location of these sensors 
can be seen in figure 9.
Figure 30 Pressure Sensor Location First Generation (Left) ; Second Generation 
(Right)
The mounting and incorporation of these sensors into the system changed from the first to 
second generation.  The open mounting of the first generation was not appropriate for 
clinical testing, thus the sensors were imbedded into the probe through a slit in the side of 
the base.  A “pressure cylinder” (figure 10) was added on top of the pressure sensors to 
measure the pressure at the surface.  
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Figure 31 Pressure Cylinder
Belleville washers were also added between the pressure cylinder and the FSR’s in order 
to provide a pre-load on the sensors.  This was necessary due to the insensitive properties 
of the FSR’s at low load levels.  This is illustrated in figure 11.
Figure 32 Sensitivity property of the FSR's
The pre-load was adjustable by a set screw that contacted the pressure cylinder in the 
sloped portion.   As the set  screw was tightened,  it  slid  up the sloped portion of  the 
cylinder, creating more pressure on the Belleville washer, more pre-load and therefore 
skipping past the insensitive range of the FSR’s.  In order to give stronger signal, the 
surface area of pressure sensors was increased by adding rectangular delrin pieces.  These 
are white in figure 9.  This increased the voltage output reading from about .25 volts to 
about 2.5 volts.  
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An amplifying  circuit  was  also  constructed  to  increase  the  sensitivity  of  the 
FSR’s.  The general circuit can be seen in figure 12.  The resistor was added specifically 
to increase the sensitivity of the FSR’s,  meaning that  a lower load would result  in a 
higher voltage output.  The capacitor was added to decrease the noise in the system and 
give a more consistent output.  
Figure 33 Circuit used for FSR's
One side of the probe contains the FSR previously described while the second 
side contains a pressure switch that outputs either an “on” signal of the input (about 6V) 
or an “off” signal of about 0V.  This signal was necessary in ensure that if the FSR was 
not sufficiently sensitive on the breast tissue there is still some measure of pressure.  This 
is not the anticipated case, but must be accounted for to ensure some measure of steady 
pressure exists.  This sensor used the same circuit (figure 12) as the FSR, only the 2000 
ohm resistor was replaced with a 200 ohm resistor.
3.2 c) Ultrasound Function
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The remaining modality of the probe is the Ultrasound.  This consists of the clinical 
Ultrasound probe and an ultrasound transducer.  The main design implementation for the 
Ultrasound was to design a snap in mechanism to fix the Ultrasound to the base.  It also 
needed to have a clear path to obtain its signal without interference from the NIR while 
also  measuring  from  the  same  location  as  the  NIR  readings  were  being  taken  thus 
ensuring a co-registration of the images.  A spring loaded snap in device was constructed 
to meet these requirements.  Also, a hole was cut through the base to the bottom of the 
Ultrasound probe to allow for a clear signal path.  This hole location can be seen in figure 
13 outlined in red.
Figure 34 Ultrasound window location
4.0) Methodology
4.1) Benchtop Testing
Additional Materials List:
Peristaltic Pump
Tissue Simulating Phantom[18]
Tubing (.40 cm diameter) ………………………………… Fisher Labs
India Ink………………………………………………….. McMaster Carr
Dry Skim Milk…………………………………………… Grocery
Quiktest™ load frame microtester (Enduratec, Eden Prairie, MN)
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The first generation probe was primarily constructed to verify the hypothesis of 
NIR and US co-registration to measure scattering and absorption properties in the blood. 
The general schematic for the bench-top test can be seen in figure 14.
Figure 35 Benchtop testing setup
The testing procedure was to pump a mixture containing skim milk and India Ink 
through the tissue simulating phantom and record measurements with the probe.  The 
tissue simulating phantom is  a technology previously developed within our lab group 
[18].  The skim milk approximately matches the scattering properties of human tissue, 
and the India Ink was used to change the absorption properties.  Ink was added in 25 µL 
increments to the skim milk mixture to change the level of absorption.  The concentration 
of skim milk could be adjusted to change the scattering coefficient of the mixture.  At 
each new ink level, the absorption level was measured with both the Tissue Oximeter and 
with the DNIRUS probe.  Ultrasound data was also simultaneously taken to produce a co-
registered image reconstruction.  The NIR and US data was then used to perform image 
reconstruction and calculate the simulated tumors absorption coefficients.  This was then 
compared with the direct data taken from the Tissue Oximeter.
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4.2) Compression Profile
In order to accurately measure the dynamic response of the tissue, an accurate 
pressure  measurement  had  to  be  obtained.   Since  the  probe  is  user  controlled,  not 
automated, this means that the user must be able to provide a constant steady pressure to 
the  tissue.   This  feasibility  was  studied  by  generating  a  square  wave  profile  using 
labview, then simultaneously plotting this profile with the real time pressure produced by 
the user.  This gave a measure of how well a user could be trained to give a constant 
repeated pressure measurement.
The pressure sensors were calibrated using a  Quiktest™ load frame microtester 
(Enduratec, Eden Prairie, MN).  Loads from 0-5500 Pa were applied be the load frame on 
to the  probe.  Three measurements were taken at each load to minimize error.  A fifth 
order polynomial was then fitted to the data points.  This curve can be seen in figure 15.
y = 76.968x5 - 471.68x4 + 1227.2x3
       - 1089.5x2 + 995.47x - 1.1836
R2 = 0.9999
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Figure 36 Calibration of the pressure sensors
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The R2  value  was  greater  than  .9999,  indicating  a  good fit  of  the  curve  to  the  data. 
Additionally, no significant hysteresis was observed during this testing.  For the tests, a 
stepped compression profile was generated for the user to follow with a peak load of 
about 5000 Pa.
4.3) Clinical Trial 
The clinical trial is being conducted at the James Care Cancer Center in Dublin, 
Ohio. This clinical trial protocol has been approved by The Ohio State University Cancer 
IRB (protocol #: 2008C0006). The testing procedure begins after a patient has met the 
qualifications for the study and agreed to take part.  The testing area and general setup 
can be seen in figure 16.  
Figure 37 Clinical trial set up
A mammogram and Ultrasound are run according to normal testing procedures at the 
clinic.  From this, a tumor location is found.  The patient then moves to the testing room 
for the trial measurements while their mammogram and US tests are being analyzed.  
Prior  to  the  patient  arriving,  the  system  is  calibrated  with  custom  software 
developed by Hamid El-Dahdah from our lab group.  This Labview software contains a 
Graphical User Interface for easy training. The trial testing begins with locating the tumor 
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with the US on the DNIRUS probe.  After the tumor is located, preliminary images are 
taken at 0, 45, 90 and 135 degrees. These images are also taken at the identical location 
on the healthy breast.  Next the stepped compression profile begins.  The nurse follows 
the profile provided by the computer through 10 pressure peaks.  This is repeated for a 
total of 5 tests.  Then the same 5 tests are run on the healthy breast tissue for comparison 
background data to be used when the data analysis is performed.
5.0) Results and Discussion
5.1) Bench Top Results
Figure 17 shows an Ultrasound image acquired during the benchtop testing of the 
first generation DNIRUS probe.  From this Ultrasound image dimensions and location 
information  was taken  using  a  least  square  fitting  technique.   From this  information 
reconstruction of the 
Figure 38 US image of the embedded tubing in tissue simulating phantom
embedded heterogeneity was performed and absorption information was determined. The 
absorption and scattering properties of the phantom were characterized by the Oxiplex™ 
tissue  oximeter  ( aµ  =  0.0147 cm-1,  s'µ = 5.2665 cm -1).   The  data  at  the  first  ink 
concentration level was used as the calibration.  Figure 18 shows a graph of the actual 
absorption levels versus the reconstructed levels. This data had an R2 value of greater 
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than .989.  There are several possible sources of error from these tests which include a 
mismatched boundary condition at the gel wax-liquid interface, NIR measurement error 
in  the  background  absorption  and  scattering  coefficients,  as  well  as  error  in  the 
Ultrasound measurement  of the tubing location and dimensions.   These errors can be 
reduced by using an embedded solid tumor simulator and improving the US algorithms as 
well as obtaining more accurate NIR measurements.
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Figure 39 Correlation between acutal and reconstructed absorption levels.  R2 = .
999
Other limitations of the system include that it can only solve for four unknown 
variables.  Since breast tissue is almost always heterogeneous, it is necessary to include 
the  ability  to  solve  for  more  than  one  unknown  heterogeneity.   The  system  can 
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accomplish this as long as the boundaries are clearly defined.  If the tissue has more than 
four unknown heterogeneities then the system may not be appropriate.  This could be 
overcome by adding more optical measurements and improving the imaging algorithm. 
Another limitation of the system is that unlike the essentially two dimensional tubing 
used in the benchtop testing, a tumor is 3D.  This is overcome by taking cross sectional 
Ultrasound measurements  from different  angles  and then estimating  the 3D geometry 
from these images.  An additional complication is that the structural boundary found from 
the  Ultrasound  may  not  represent  the  functional  boundary  found  from  the  NIR 
measurements.   This  could  possibly  be  resolved  in  the  short  term  by  adding  a 
computational offset to the Ultrasound measurements.
Figure 19 shows some detailed results of the compression testing.  As previously 
noted, reliable pressure data is necessary in order to measure dynamic response of the 
breast tissue.  In Figure 19, the dashed line represents the computer generated profile and 
the solid line is the user response to the profile.  Data to note from this figure is that the 
average time delay during the                                                         
Figure 40 Details of compression profile
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compression (dt1 in Figure 19) is 0.905 ± 0.035 second; and the averaged release time 
delay dt2 is 1.083 ± 0.110 second.  You can also observe that there is some fluctuation 
during the first part of the compression phase, t1 which is followed by a much more stable 
phase, t2.  This stable compression phase was repeated in each of the five subjects who 
performed this test. The results of the tests were analyzed and it was found that during t2 
the accuracy of the compression load reaches 95.7% of the compression target and the 
relative pressure deviation is less than 5%.  It is within this time phase that the NIR 
measurements should be taken for maximum accuracy. 
5.2) Clinical Trial Results
The current clinical trial is still ongoing and does not have preliminary results yet. 
Testing for the clinical trial will continue until reliable data is taken with a clear boundary 
established  by  the  Ultrasound.   This  data  will  then  be  analyzed  to  determine  if  the 
hypothesis  that changes in the neovasculure process within tissue bearing cancer may 
cause  an increase  in  vasculure  resistance  which causes  a  slower [Hbt]  response  than 
normal healthy tissue is true, as well as that high hemoglobin levels and low oxygen 
levels are associated with a tissue lesion being malignant.
6.0) Conclusions and Future Work
6.1) Conclusions
In conclusion a prototype was developed using the combined modalities of Near 
Infra red and Ultrasound to measure the relative changes of breast tissue in response to 
dynamic pressure stimuli.  A benchtop model was constructed that validated the ability to 
accurately reconstruct  the absorption properties  of a  tissue simulating  phantom.   The 
benchtop  model  also  validated  the  ability  of  a  user  to  accurately  follow a  computer 
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generated pressure profile.  This data from benchtop testing is being used to optimize the 
clinical trial set-up.  A second prototype was developed for use in the current ongoing 
clinical trial.  The current clinical trial will be continued to obtain results to confirm the 
initial hypothesis.
6.2) Future Work
There are many directions for the future work of this research to continue.  Of 
primary  importance  is  to  finish  the  current  clinical  trial  to  validate  the  use  of  the 
combined modalities as a legitimate way to diagnose cancer malignancy.   If  the trial 
proves successful, modifications may be made to improve the malignancy index defined 
in previous clinical trials.
Some limitations of the current research include the inability of the orthogonal 
Ultrasound to obtain accurate images of the 3D breast lesions.  The plan to overcome this 
liability  is  to  integrate  a  3D  volumetric  Ultrasound  into  the  current  system.   Also, 
differences between the functional and structural boundaries could lead to inaccuracies of 
NIR measurements.  This can be overcome through the use of a contrast agent that has 
both Ultrasound and NIR sensitivity.  This would give an accurate co-registered NIR and 
US image.  This could be accomplished with the help of micro and nano bubbles which 
could  be  injected  with  an  encapsulated  dual  sensitive  contrast  agent.   Some work  is 
currently being done in our lab towards the construction of these bubbles.  Figure 20 
shows a SEM image of these bubbles constructed.  Figure 21 shows the size distribution 
for  the  micro  and  nano  bubbles.   With  an  attached  antibody  that  would  create  an 
attraction to the cancer site, the micro/nano bubbles would cluster at the cancer site.  The 
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bubbles could then be broken through either the use of concentrated Ultrasound signals or 
some other method.  The contrast agent inside would then be released,  saturating the 
cancer site and creating an accurate functional and structural boundary.
Figure 41 Microbubble Construction
 
                                                                Figure 42 Micro and nano bubble distribution
This  technology could  then  be  integrated  for  use  in  other  ways  such  as  with 
cancer ablation.  Figure 22 shows one way that this technology could be used to improve 
cancer treatment through ablation.  
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Figure 43 Possible use with cancer ablation
 The basic process would be an injection of the contrast agent followed by pre-operative 
analysis using the DNIRUS technology to detect the tumor boundary.  The system could 
then be used intra-operatively with cancer ablation techniques to monitor the boundary of 
tissue cooked.  This would occur in an iterative process until it was determined the cancer 
was completely removed.  Then a post operative analysis could be performed for a final 
check of the boundary.  Utilization of this technology with current techniques such as 
Radio Frequency Ablation could lead to a significant decrease in breast cancer related 
deaths.
xxx
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